Patricia Pozo-Rosich
Overview
Explore the profile of Patricia Pozo-Rosich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
3315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sacco S, Ashina M, Diener H, Haghdoost F, Lee M, Monteith T, et al.
Cephalalgia
. 2025 Feb;
45(2):3331024251320608.
PMID: 39980456
Migraine is one of the most prevalent and disabling neurological diseases, significantly affecting quality of life and productivity, as well as contributing to substantial societal costs. Recent innovations, including calcitonin...
2.
Gine-Cipres E, Torres-Ferrus M, Gallardo V, Ruiz A, Caronna E, Pozo-Rosich P
Pain Manag Nurs
. 2025 Jan;
PMID: 39799047
Purpose: Headache is a prevalent and highly disabling neurological disorder. There are no data on its prevalence in and impact on hospitalized patients. The objective of this study was to...
3.
4.
Gottschalk C, Gandhi P, Pozo-Rosich P, Christie S, Tassorelli C, Stokes J, et al.
Cephalalgia
. 2024 Dec;
44(12):3331024241300305.
PMID: 39648617
Background: We aimed to assess the effects of preventive migraine treatment with atogepant vs. placebo on patient-reported quality of life and functioning. Methods: Analyses of patient-reported outcomes from three 12-week,...
5.
Pozo-Rosich P, Garcia-Azorin D, Diaz-Cerezo S, Fernandez-Montoya J, de Paz H, Nunez M
Front Neurol
. 2024 Dec;
15:1502475.
PMID: 39639987
Introduction: In the context of migraine preventive therapy, new therapeutic modalities such as monoclonal antibodies targeting the calcitonin gene-related peptide receptor (CGRP) or ligand offer potential advantages over traditional preventive...
6.
Ailani J, Lalla A, Halker Singh R, Holle-Lee D, Nagy K, Kelton K, et al.
Cephalalgia
. 2024 Nov;
44(11):3331024241299377.
PMID: 39558612
Background: To evaluate the benefit-risk assessment of atogepant and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) vs. placebo based on the number needed to treat (NNT) and the number needed...
7.
Gonzalez-Martinez A, Ray J, Haghdoost F, Ashraf U, Cerrahoglu Sirin T, Dantes M, et al.
Cephalalgia
. 2024 Nov;
44(11):3331024241297652.
PMID: 39558611
Background: Time in headache disorders is crucial for diagnosis and gives insight into headache pathophysiology. Objective: To summarize published studies which describe timing processes in both attack presentation (onset, duration)...
8.
Cammarota F, De Icco R, Vaghi G, Corrado M, Bighiani F, Martinelli D, et al.
Cephalalgia
. 2024 Oct;
44(10):3331024241291578.
PMID: 39434667
Background: High-frequency episodic migraine (HFEM) has gained attention in the field of headache research and clinical practice. In this narrative review, we analyzed the available literature to assess the evidence...
9.
Sebastianelli G, Atalar A, Cetta I, Farham F, Fitzek M, Karatas-Kursun H, et al.
Cephalalgia
. 2024 Oct;
44(10):3331024241287224.
PMID: 39380339
Background: The prodrome or premonitory phase is the initial phase of a migraine attack, and it is considered as a symptomatic phase in which prodromal symptoms may occur. There is...
10.
Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrus M, Pozo-Rosich P
Cephalalgia
. 2024 Sep;
44(9):3331024241273966.
PMID: 39314064
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period...